UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

03 ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

Read More Share:

Dec

02 UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Read More Share:

Dec

01 UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Read More Share:

Dec

01 Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

Read More Share:

Nov

29 Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

Read More Share:

Nov

27 UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

Read More Share:

Nov

17 Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

Read More Share:

Nov

14 UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:

Nov

11 Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

Read More Share:

Nov

10 UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

Read More Share:

Categories

Archives

Jan

03

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

Dec

02

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Dec

01

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Dec

01

Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

Nov

29

Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

Nov

27

UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

Nov

17

Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Nov

11

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

Nov

10

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Notice about cookies

Categories

Archives

Jan

03

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

Dec

02

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Dec

01

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Dec

01

Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

Nov

29

Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

Nov

27

UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

Nov

17

Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Nov

11

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

Nov

10

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact